Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)
China · Delayed Price · Currency is CNY 13.74
-0.18 (-1.29%)
Aug 14, 2026, 3:04 PM CST
SHE:002755 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 1,752 | 1,779 | 1,778 | 1,443 | 1,873 | 3,107 |
Revenue Growth | -4.65% | 0.08% | 23.15% | -22.92% | -39.72% | -17.87% |
Gross Profit Gross Profit Growth | 1,411 | 1,426 | 1,444 | 1,166 | 1,627 | 2,830 |
Operating Income Operating Income Growth | 253.87 | 192.85 | 94.55 | -290.49 | -313.2 | 309.73 |
Net Income Net Income Growth | 266.34 | 236.6 | 160.29 | -148.53 | -225.83 | 379.91 |
Earnings Per Share EPS Growth | 0.28 | 0.25 | 0.17 | -0.16 | -0.24 | 0.41 |
EPS Growth | 38.32% | 47.06% | - | - | - | -47.44% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Anti-infection Anti-infection Growth | 399.47 | 493.92 | 282.34 | 162.25 | - |
Anti-Tumor Anti-Tumor Growth | 710.57 | 631.18 | 616.95 | 651.41 | 799.71 |
Chronic Diseases Chronic Diseases Growth | 395.28 | 323.39 | 205.14 | 145.74 | - |
Digestive Digestive Growth | 218.93 | 269.9 | 299.01 | 856.01 | 1,906 |
Other Category Other Category Growth | 10.84 | 22.2 | 26.25 | 43.55 | 335.7 |
Unallocated Other Operations Unallocated Other Operations Growth | 43.93 | 37.05 | 13.77 | 13.61 | 65.22 |
Total Total Growth | 1,779 | 1,778 | 1,443 | 1,873 | 3,107 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 2,481 | 2,481 | 2,095 | 1,761 | 1,612 | 1,688 |
Total Debt Total Debt Growth | 6.31 | 33.83 | 72.67 | 123.8 | 57.41 | 14.13 |
Net Cash (Debt) Net Cash Growth | 2,474 | 2,447 | 2,022 | 1,637 | 1,554 | 1,674 |
Net Cash Growth | 11.10% | 21.01% | 23.52% | 5.32% | -7.14% | 15.51% |
Net Cash Per Share Net Cash Per Share Growth | 2.60 | 2.59 | 2.14 | 1.76 | 1.65 | 1.81 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 652.66 | 651.64 | 411.36 | -26.57 | -52.81 | 567.71 |
Capital Expenditures CapEx Growth | -296.78 | -143.58 | -230.42 | -129.32 | -150.45 | -133.76 |
Free Cash Flow Free Cash Flow Growth | 355.88 | 508.07 | 180.94 | -155.89 | -203.27 | 433.95 |
Free Cash Flow Growth | 81.17% | 180.79% | - | - | - | 13.99% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 80.54% | 80.14% | 81.24% | 80.77% | 86.88% | 91.08% |
Operating Margin | 14.49% | 10.84% | 5.32% | -20.13% | -16.73% | 9.97% |
Pretax Margin | 17.93% | 14.23% | 8.52% | -13.92% | -14.02% | 13.07% |
Profit Margin | 15.20% | 13.30% | 9.02% | -10.29% | -12.06% | 12.23% |
FCF Margin | 20.31% | 28.56% | 10.18% | -10.80% | -10.85% | 13.97% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.120 | 0.120 | 0.120 | - | - | 0.100 |
Dividend Per Share Growth | 0% | 0% | - | - | - | -50.00% |
Dividend Yield | 0.87% | 0.74% | 0.96% | - | - | 0.81% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 49.16 | 64.06 | 73.60 | - | - | 31.10 |
Forward PE | - | 85.95 | 231.09 | 15.30 | 15.30 | 15.30 |
P/FCF Ratio | 35.83 | 29.83 | 65.20 | - | - | 27.23 |
PS Ratio | 7.28 | 8.52 | 6.64 | 6.96 | 3.94 | 3.80 |